Oliver Jeffery
Neurology · Englewood, CONPI 1083929160
Payments from drug & device makers
Across 216 payments — averaging $28.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- UCB, Inc.$981
- DIXI Medical USA Corp$833
- SK Life Science, Inc.$429
- Novartis$407
- Jazz Pharmaceuticals Inc.$284
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,98098%
- Education$1422%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 54 | $1,290 |
| UCB, Inc. | 36 | $981 |
| DIXI Medical USA Corp | 1 | $833 |
| SK Life Science, Inc. | 13 | $429 |
| Novartis | 23 | $407 |
| Jazz Pharmaceuticals Inc. | 6 | $284 |
| Pfizer | 13 | $261 |
| Teva Pharmaceuticals USA, Inc. | 9 | $247 |
| EMD Serono, Inc. | 9 | $171 |
| MDD US Operations, LLC | 7 | $165 |
| Microvention, Inc. | 1 | $150 |
| Amgen | 4 | $105 |
| Greenwich Biosciences, Inc. | 3 | $104 |
| Catalyst Pharmaceuticals, Inc. | 4 | $80 |
| Axsome Therapeutics, Inc. | 3 | $69 |
| Eisai Inc. | 3 | $59 |
| Neuropace, Inc. | 2 | $55 |
| ANI Pharmaceuticals, Inc. | 2 | $50 |
| Neurelis, Inc. | 2 | $39 |
| Acadia Pharmaceuticals Inc | 2 | $36 |
| Biogen | 2 | $33 |
| Sunovion Pharmaceuticals Inc. | 2 | $32 |
| Tanabe Pharma America, Inc. | 2 | $30 |
| Neurocrine Biosciences, Inc. | 2 | $27 |
| Medtronic | 1 | $22 |
| Arbor Pharmaceuticals, Inc. | 1 | $20 |
| Boston Scientific | 1 | $19 |
| Impel Pharmaceuticals Inc. | 1 | $18 |
| Adamas Pharmaceuticals, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Livanova USA, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Chaperon Guiding Catheter$150
- Azur CX Detachable$150
- ERIC RETRIEVAL DEVICE$150
- Epidiolex$139
- XCOPRI$125
How this compares
$6,122 in reported general payments places this provider in the 60th percentile of 334 neurology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 147 | $204,754 |
| IngrezzaValbenazine Tosylate | 23 | $192,876 |
| EpidiolexCannabidiol (Cbd) | 31 | $128,364 |
| AptiomEslicarbazepine Acetate | 87 | $127,993 |
| BriviactBrivaracetam | 46 | $94,210 |
| OnfiClobazam | 12 | $43,817 |
| FycompaPerampanel | 24 | $30,894 |
| Lacosamide | 276 | $30,332 |
| VimpatLacosamide | 20 | $25,956 |
| Clobazam | 124 | $15,600 |
| LamictalLamotrigine | 14 | $15,556 |
| ValtocoDiazepam | 22 | $14,926 |
| Levetiracetam | 243 | $10,036 |
| Emgality SyringeGalcanezumab-Gnlm | 12 | $8,195 |
| Lamotrigine | 202 | $4,438 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $429 | $204,754147 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $27 | $192,87623 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $32 | $127,99387 claims |
| UCB, Inc.Briviact, Vimpat | $981 | $120,16666 claims |
| Eisai Inc.Fycompa | $59 | $30,89424 claims |
| Neurelis, Inc.Valtoco | $39 | $14,92622 claims |
| PfizerDilantin | $261 | $2,55925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 334 neurology providers in Colorado.
Other neurology in Englewood
- Rajeev KumarEnglewood$14.3M
- Meagen SalinasEnglewood$1.3M
- Marc TreihaftEnglewood$673K
- Cori MillenEnglewood$621K
- Kirsten BrachtEnglewood$151K
- Aaron HaugEnglewood$122K
- Michael PearlmanEnglewood$63K
- Enrique AlvarezAurora$14.3M
- Tamara MillerFort Collins$7.4M
- Alison AllenBasalt$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.